VelosBio welcomes Mark Chin to its Board along with raising $58m Series A funding co-led by Arix Bioscience and Sofinnova Ventures

– USA, CA – VelosBio Inc., a next-generation oncology company, developing novel antibody-drug conjugates (“ADCs”) to treat haematological cancers and solid tumours, raised $58m in a Series A funding round co-led by new investors Arix Bioscience plc (LSE:ARIX) and Sofinnova Ventures and including Pappas Ventures and Chiesi Ventures, as well as existing investors Takeda Ventures, Inc and Decheng Capital.…

Amplyx Pharmaceuticals announces Anand Mehra and Johan Kördel to Board along with raising $67m Series-C financing led by Sofinnova Venture Partners

– USA, CA – Amplyx Pharmaceuticals, a company developing novel antifungal agents for life-threatening fungal infections, today announced that it has raised $67 million through a Series C financing led by Sofinnova Venture Partners and including other new investors Lundbeckfonden Ventures, Arix Bioscience and Pappas Capital.…